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Abstract
 
In type 1 diabetes, autoimmune T cells cause destruction of pancreatic 
 
 
 
 cells by largely unknown
mechanism. Previous analyses have shown that 
 
 
 
 cell destruction is delayed but can occur in
perforin-deficient nonobese diabetic (NOD) mice and that Fas-deficient NOD mice do not
develop diabetes. However, because of possible pleiotropic functions of Fas, it was not clear
whether the Fas receptor was an essential mediator of 
 
 
 
 cell death in type 1 diabetes. To directly
test this hypothesis, we have generated a 
 
 
 
 cell–specific knockout of the 
 
Fas
 
 gene in a trans-
genic model of type 1 autoimmune diabetes in which CD4
 
 
 
 T cells with a transgenic TCR
specific for influenza hemagglutinin (HA) are causing diabetes in mice that express HA under
control of the rat insulin promoter. Here we show that the Fas-deficient mice develop autoimmune
diabetes with slightly accelerated kinetics indicating that Fas-dependent apoptosis of 
 
 
 
 cells is a
dispensable mode of cell death in this disease.
Key words: Fas receptor • diabetes • 
 
 
 
 cell death • autoimmunity • conditional knockout
 
Introduction
 
Nonobese diabetic (NOD) mice are thought to represent a
suitable animal model of human type 1 diabetes (1, 2). In this
model, the disease depends on the activation of autoimmune
T cells by peptides presented by the particular NOD class II
(g7) MHC allele that controls disease. In addition, several
T cell receptor transgenic models of type 1 diabetes have
been developed in which particularly high frequencies of
CD4 or CD8 T cells specific for antigens expressed in 
 
 
 
cells cause pancreatic islet cell infiltration with subsequent
destruction of 
 
 
 
 cells (3, 4). In the NOD and in some
transgenic models (3, 5, 6), the disease can be precipitated
when CD4 T cells from diabetic mice are transferred into
immunodeficient recipients where diabetes develops within
1–2 wk. Nevertheless, the mechanism of 
 
 
 
 cell destruction
has remained obscure. It became clear that perforin-deficient
NOD mice exhibited a delayed onset of disease (7, 8), but
it was not obvious whether the late phase of 
 
 
 
 cell destruction
was affected. On the other hand, it was shown that Fas-
deficient lpr/lpr mice on the NOD background did not
develop diabetes (9). Additional analyses had suggested that
Fas was present on 
 
 
 
 cells (9) and that expression increased
during development of the disease. Other studies, however,
also revealed that in Fas-deficient NOD mice there was no
infiltration of pancreatic islets by mononuclear cells (10),
thus leaving open the question of whether Fas was directly
involved in 
 
 
 
 cell death. More recent studies using a dominant
negative 
 
Fas
 
 mutation (11) or in vivo anti-Fas L antibody
treatment (12) were interpreted to indicate that Fas may
have a role in promoting predominantly early stages of the
disease. To address a potential role of Fas in 
 
 
 
 cell destruction
conclusively, we have produced a conditional 
 
Fas
 
 allele
(fas
 
fl
 
) in which the death domain-encoding exon 9 is
flanked by loxP sites, allowing for cell type–specific Fas
inactivation (unpublished data). To analyze whether Fas
inactivation in pancreatic 
 
 
 
 cells resulted in resistance to
the development of diabetes, the fas
 
fl
 
 allele and a rat insulin
promoter (RIP)–controlled Cre transgene (13) were intro-
duced into a transgenic model of type 1 diabetes in which a
transgenic TCR recognizes peptide 111–119 of influenza
hemagglutinin (HA) expressed under control of the RIP
and presented by class II E
 
d
 
 MHC molecules (TCR-HA,
Ins-HA) (5). The onset and development of diabetes in I-E
 
d
 
homozygous mice carrying the five transgenes (TCR-HA
 
 
 
/
 
 
 
,
Ins-HA
 
 
 
/
 
 
 
, Fas
 
fl/fl
 
, RIP-Cre
 
 
 
/
 
 
 
 mice) was compared with
 
Address correspondence to Harald von Boehmer, Harvard Medical School,
Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115, Phone:
(617) 632-6882; Fax: (617) 632-6881; e-mail:
Harald_von_Boehmer@dfci.harvard.edu
 
Abbreviations used in this paper: 
 
HA, hemagglutinin; NOD, nonobese dia-
betic; RIP, rat insulin promoter.T
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that in mice with only four transgenes lacking the RIP-cre
transgene (TCR-HA
 
 
 
/
 
 
 
, Ins-HA
 
 
 
/
 
 
 
, Fas
 
fl/fl
 
, RIP-Cre
 
 
 
/
 
 
 
mice) and thereby expressing Fas in 
 
 
 
 cells.
 
Materials and Methods
 
Mice and Genotyping.
 
TCR-HA mice and Ins-HA mice were
bred as heterozygous transgenic mice and are on the BALB/c back-
ground. Fas
 
fl
 
 mice derived from C57Bl/6 were created by homolo-
gous recombination using a conditional 
 
Fas
 
 allele in which the
exon 9 has been flanked by loxP sites. RIP-Cre mice were on a
mixed 129sv, C57Bl/6, and DBA-2 background (13). All animals
were maintained in a pathogen-free facility in accordance with the
guidelines of the Committee on Animals of Harvard Medical
School. Genotyping of transgenes was determined by PCR on tail
DNA. Primer sequences were 5
 
 
 
-GGCTACCATGCGAACAAT-
TCACCCG-3
 
 
 
 and 5
 
 
 
-CTCCGTCAGCCATAGCAAATTT-
CTG-3
 
 
 
 for the 
 
HA
 
 transgene, 5
 
 
 
-ACAAGGTGGCAGTAA-
CAGGA-3
 
 
 
 and 5
 
 
 
-ACAGTCAGTCTGGTTCCTGA-3
 
 
 
 for the
 
TCR-HA
 
 transgene, 5
 
 
 
-CGATGCAACGAGTGATGAGG-3
 
 
 
 and
5
 
 
 
-CATCGCTCGACCAGTTTAGT-3
 
 
 
 for the 
 
Cre
 
 trans-
gene, and 5
 
 
 
-TGCAGTTGCTGAGATGAACCATTTTCTCT-
GTCT-3
 
 
 
 (P1) and 5
 
 
 
-GGCTTTGGAAAGGAATTTCCTC-
CTAAGAGG-3
 
 
 
 (P2) for WT and floxed 
 
Fas
 
 alleles. A 430-bp
amplified product indicated the presence of a WT 
 
Fas
 
 allele,
whereas a 470-bp amplified product indicated the presence of a
floxed 
 
Fas
 
 allele, since the sense primer was located in exon 9 and
the antisense one 3
 
 
 
 to the loxP site downstream of exon 9 (Fig. 1
A). Homozygosity for I-E
 
d
 
 was determined by staining peripheral
blood leukocytes.
 
RIP-Cre–mediated Fas Recombination in Islet DNA.
 
DNA was
prepared from the thymus, liver, heart, and islets isolated at the
Harvard Medical School Islet Core Rodent Isolation. RIP-Cre–
mediated 
 
Fas
 
 recombination was assessed using a sense primer
with the sequence 5
 
 
 
-GTCCTCTATTATCCTCATCATGAG-3
 
 
 
(P3) located upstream of the 5
 
 
 
 loxP site and the antisense primer
located downstream of the 3
 
 
 
 loxP site (P2). A 1.7-kb amplified
product indicated the presence of intact exon 9, whereas a 260-bp
amplified product indicated the presence of a deleted exon 9.
 
Diabetes Monitoring and Cyclophosphamide Administration.
 
De-
velopment of spontaneous diabetes was assessed by measuring
 
blood glucose twice a week with an automatic glucometer
(Accu-chek Advantage; Roche). Cyclophosphamide (Sigma-
Aldrich) in PBS was injected intraperitoneally at a dose of 200
mg/kg. Blood glucose levels of cyclophosphamide-treated mice
were monitored daily.
 
Adoptive Transfer of Diabetes.
 
CD4
 
 
 
 TCR-HA–expressing
cells were purified by sorting lymphocytes from spleen and LN
of RAG-2
 
 
 
/
 
 
 
, TCR-HA
 
 
 
/
 
 
 
 mice stained with the 6.5 (anti–
TCR-HA) and anti-CD4 (GK1.5; BD Biosciences) mAbs. 10
 
5
 
sorted 6.5
 
 
 
CD4
 
 
 
 cells were i.v. injected into either RAG-2
 
 
 
/
 
 
 
,
Fas
 
fl/fl
 
, Rip-cre
 
 
 
/
 
 
 
, Ins-HA
 
 
 
/
 
  
 
or RAG-2
 
 
 
/
 
 
 
, Fas
 
fl/fl
 
, Rip-cre
 
 
 
/
 
 
 
,
Ins-HA
 
 
 
/
 
 
 
 mice. Blood glucose levels of the recipients were
tested daily.
 
Results and Discussion
 
The efficacy and tissue specificity of Cre-mediated dele-
tion of 
 
Fas
 
–exon 9 was assessed by PCR on DNA prepared
from purified islets and various tissues from Cre-expressing
and -nonexpressing Fas
 
fl
 
 homozygous mice. Fig. 1 A depicts
a schematic representation of mutated and WT 
 
Fas
 
 alleles
and the position of the primers used to assess littermate ge-
notype and 
 
 
 
 cell-specific loss of functional 
 
Fas
 
 allele. Fig.
1 B
 
 
 
shows that,
 
 
 
regardless of Cre expression, DNA of non-
pancreatic origin yielded a single 1.7-kb P2/P3 PCR prod-
uct indicative of the sole presence of 
 
Fas
 
–exon 9 (Fig. 1 A).
Even traces of recombined 
 
Fas
 
–exon 9 would have been
detected by the presence of a 260-bp fragment, which be-
cause of its short size would be favored over the 1.7-kb
fragment. Evidence for islet-specific Cre-mediated deletion
of exon 9 came from the single 260-bp P2/P3 PCR prod-
uct that was obtained from islets of Cre-expressing mice,
whereas a single 1.7-kb band was detected from the islets of
Cre-nonexpressing mice. PCR analysis of the same samples
using the P1/P2 primers that hybridize to
 
 
 
WT nonrecom-
bined but not to recombined 
 
Fas 
 
alleles (Fig. 1 A) yielded a
single 470-bp band in nonpancreatic tissues of mice irre-
spective of RIP-Cre expression and in islets of mice lacking
RIP-Cre (Fig. 1 B). A much fainter 470-bp band was seen
Figure 1. Successful elimination of the floxed Fas–exon 9 by homologous recombination in pancreatic   cells. (A) Representation of WT Fas, floxed
Fas, and recombined floxed Fas alleles, and location of the primers used in PCR analyses. Cre-mediated recombination of the floxed Fas allele results in
the deletion of exon 9. (B) PCR analysis on DNA from liver, heart, thymus, and purified islets of one Fasfl homozygous and one Fasfl homozygous, RIP-
Cre heterozygous mouse.T
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in islets of Cre-expressing mice (Fig. 1 B). This faint band is
likely to reflect the fact that whole islets such as those used
in the present study contain cells other than   cells ( 30%),
e.g., non–  endocrine cells, macrophages, endothelial cells,
etc., lacking Cre expression. Thus, the absence of amplifica-
tion of a 260-bp P2/P3 PCR product (which will be fa-
vored over the 1.7-kb P2/P3 PCR product) in nonpancre-
atic tissues and its detection only in Cre-expressing islets and
the diminution of the 470-bp fragment intensity in Cre-
expressing islets strongly suggest that the RIP-Cre–mediated
recombination resulted in tissue-specific deletion of func-
tional Fas in the vast majority of   cells. Since the develop-
ment of diabetes with blood sugar levels exceeding 200 mg/
dl requires destruction of well over 50% of all   cells, the
conditional knockout was suitable to reveal a possible essen-
tial role of Fas in the development of diabetes, since any
Fas-dependent destruction of   cells could not exceed 50%
in these particular mice, and thus be insufficient to result in
diabetes. Previous work using a RIP-Cre transgenic mouse
line identical to that of the present study could not find evi-
dence for a toxic effect of the transgene to the   cells, their
function, or the glucose tolerance of RIP-Cre transgenic
mice (13, 14). Furthermore, the Fasfl heterozygous, TCR-
HA, Ins-HA, RIP-Cre transgenic breeders used in this
study to generate the Fas-competent and -deficient TCR-
HA, Ins-HA mice behaved identically to TCR-HA, Ins-
HA double transgenic mice with respect to diabetes devel-
opment, fertility, and frequency of the expected genotypes
among their litter. Thus, we could exclude a role for the
RIP-Cre transgene in potential phenotypical differences be-
tween RIP-Cre–expressing and –nonexpressing mice. To
assess the impact of Fas expression by   cells in their T cell–
mediated destruction, we compared the development of
spontaneous autoimmune diabetes in the TCR-HA, Ins-
HA transgenic model in which the floxed Fas alleles are
recombined by the Cre recombinase (TCR-HA / , Ins-
HA / , Fasfl/fl, RIP-Cre /  mice) to that of transgenic lit-
termates lacking Cre expression (TCR-HA / , Ins-HA / ,
Fasfl/fl, RIP-Cre /  mice) (Fig. 2). The incidence and onset
of diabetes in the latter quadruple transgenic littermates was
not different from that in TCR-HA, Ins-HA double trans-
genic mice, indicating that neither the introduced floxed
Fas alleles nor the mixed genetic background brought by
the Fas floxed and RIP-Cre transgenic mice did perturb au-
toimmunity. The elimination of Fas by Cre recombinase
did not produce a delay in the onset but some acceleration
of the onset of diabetes (Fig. 2). A similar conclusion,
namely that Fas deficiency did not delay the onset of diabe-
tes, was reached when diabetes was analyzed in TCR-HA,
Ins-HA mice transgenic mice with a   cell–specific deletion
of Fas that were treated with 200 mg/kg cyclosphospha-
mide. This treatment is known to precipitate diabetes in
NOD and TCR-HA, Ins-HA mice with similar kinetics,
perhaps by interfering with regulatory (suppressive) T cells
that control the development of disease. The RIP-Cre–
expressing mice came down with diabetes 4–5 d after treat-
ment with the drug, indicating that also under these condi-
tions Fas did not play a discernible role in   cell death
caused by autoimmune T cells (Fig. 3). Finally, it was tested
Figure 2. Effective destruction of  -islet cells from Fas-deficient and
Fas-competent TCR-HA, Ins-HA transgenic mice. Blood glucose levels
of Fasfl/fl, Rip-Cre / , TCR-HA / , Ins-HA /  ( , n   46) and Fasfl/fl,
Rip-Cre / , TCR-HA / , Ins-HA /  ( , n   63) mice were assessed
over a period of 32 wk. Mice were considered diabetic after two successive
blood glucose measurements  300 mg/dl.
Figure 3. Cyclophosphamide-induced diabetes in TCR-HA / ,
Ins-HA / , Fasfl/fl, RIP-Cre /  mice. Mice (n   10) were injected with
200 mg/kg of cyclophosphamide on day 0 and monitored for their blood
glucose levels every day.
Figure 4. Development of diabetes in Fas-deficient and Fas-competent
RAG-2 / , Ins-HA /  recipients injected with CD4  TCR-HA trans-
genic cells. 6.5 CD4  cells from RAG-2 / , TCR-HA /  mice were
sorted, and 105 cells were transferred into RAG-2 / , Fasfl/fl, Rip-cre / ,
Ins-HA /  ( , n   4) and RAG-2 / , Fasfl/fl, Rip-cre / , Ins-HA / 
( , n   4) on day zero. Blood glucose levels were monitored daily.T
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whether purified CD4  TCR-HA–expressing T cells from
TCR-HA transgenic RAG-2 /  mice could cause   cell
destruction in the absence of CD8  T cells by transferring
them into Ins-HA transgenic mice on the RAG-2 /  back-
ground lacking or expressing fas on   cells. As shown in Fig.
4, diabetes developed in both types of recipients within a
short time period after injection of 105 CD4  T cells.
In both the NOD model (2) and in several TCR trans-
genic models (3, 5, 6), the autoimmune disease can be trans-
ferred with purified CD4 T cells into immunodeficient
mice that themselves do not have any T cells. Since only a
few activated CD4  T cells express perforin but most ex-
press Fas ligand, it was conceivable that such T cells de-
stroyed   cells by a Fas L–Fas interaction that required di-
rect cell contact. Our findings refute this hypothesis and are
consistent with the notion that   cells from Fas-deficient
mice that were transplanted into Fas-competent mice are ef-
fectively destroyed by diabetogenic T cells (14–16) even
though it is not clear in the latter scenario whether destruc-
tion of the transplanted   cells occurs by the same mecha-
nism as that of   cells in situ. Our results are also consistent
with the finding that a dominant negative Fas transgene in
NOD mice had little effect on the development of diabetes
when splenocytes from diabetic animals were transferred
into x-irradiated transgenic nondiabetic recipients (11).
By eliminating the Fas L–Fas apoptotic system as the es-
sential mediator of   cell death in type 1 diabetes, our re-
sults should shift the focus to other mediators of apoptotic
cell death that do not require direct contact between T
cells and   cells. With regard to this notion, we may point
out that there is apparently no significant expression of class
II MHC on   islet cells (1) and perhaps even more conclu-
sively that antigen-specific contact between T cells and  
cells is not required for the T cell–mediated destruction of
  cells (17). Thus, the search for mediators of   cell de-
struction needs to focus on molecules that play an essential
role in   cell destruction in type 1 autoimmune diabetes
and differ from Fas. The identification of such essential me-
diators of   cell death would perhaps permit interference
with the disease once the process of destruction has begun
and first symptoms are detectable.
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